Invivyd Valuation Multiples

Invivyd Overview

About Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Founded

2020

HQ

Employees

100

Website

invivyd.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $70M

EBITDA: ($63M)

EV

$394M

Valuation Multiples

Multiples.vc

Start free trial

Invivyd Financials

Invivyd reported last 12-month revenue of $70M and negative EBITDA of ($63M).

In the same LTM period, Invivyd generated $64M in gross profit, ($63M) in EBITDA losses, and had net loss of ($49M).

Invivyd P&L

In the most recent fiscal year, Invivyd reported revenue of $53M and EBITDA of ($53M).

Invivyd expects next 12-month revenue of XXX and NTM EBITDA of XXX

Invivyd Stock Performance

Invivyd has current market cap of $477M, and enterprise value of $394M.

Invivyd's stock price is $1.69.

Invivyd Valuation Multiples

Invivyd trades at 5.7x EV/Revenue multiple, and (6.3x) EV/EBITDA.

Invivyd Financial Valuation Multiples

As of March 19, 2026, Invivyd has market cap of $477M and EV of $394M.

Equity research analysts estimate Invivyd's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Invivyd has a P/E ratio of (9.6x).

Invivyd Margins & Growth Rates

Invivyd's revenue in the last 12 month grew by 96%.

Invivyd's revenue per employee in the last FY averaged $0.7M.

Invivyd's rule of 40 is 5% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Invivyd's rule of X is 148% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Invivyd Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Invivyd M&A Activity

Invivyd acquired XXX companies to date.

Last acquisition by Invivyd was on XXXXXXXX, XXXXX. Invivyd acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Invivyd Investment Activity

Invivyd invested in XXX companies to date.

Invivyd made its latest investment on XXXXXXXX, XXXXX. Invivyd invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).